Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine + etoposide + cyclophosphamide + methotrexate (Centre Léon Bérard)
- Development stage
- Unknown
- Lead developer
- Centre Léon Bérard
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
VEC + methotrexate is a multi-agent combination chemotherapy regimen primarily utilized in the treatment of pediatric ependymoma, specifically within the SIOP Ependymoma II clinical trial program. The regimen consists of a standard backbone of vincristine, etoposide, and cyclophosphamide (VEC), supplemented with high-dose methotrexate (HD-MTX) followed by folinic acid rescue. This combination employs multiple cytotoxic mechanisms to target tumor cells: vincristine inhibits microtubule polymerization, etoposide targets topoisomerase II to induce DNA damage, cyclophosphamide acts as a DNA-alkylating agent, and methotrexate inhibits dihydrofolate reductase (DHFR) to disrupt DNA synthesis. It is being evaluated for its efficacy in improving survival outcomes in children and young adults with residual inoperable disease following surgery.
- Other names
- VEC plus methotrexatevincristine, etoposide, cyclophosphamide, and methotrexate
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA
Beyond the preview
Go deeper on vincristine + etoposide + cyclophosphamide + methotrexate (Centre Léon Bérard).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine + etoposide + cyclophosphamide + methotrexate (Centre Léon Bérard).